Effects of Long-Term Treatment with Topiramate on Mood and Body Weight in Patients with Bipolar Disorders

Primary Psychiatry

Volumn 10, Issue 3, 2003, Pages 63-68

  Marcotte, David B ^a  

^a Marcotte Gullick and Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; LITHIUM; TOPIRAMATE;

ARTICLE; BIPOLAR DISORDER; BODY WEIGHT; CYCLOTHYMIA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; LONG TERM CARE; MOOD; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 1842610443     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 1994;151(suppl 12):1-36.
2. Cheskin LJ, Bartlett SJ, Zayas R, Twilley CH, Allison DB, Contoreggi C. Prescription medications: a modifiable contributor to obesity. South Med J. 1999;9:898-904.
3. Chen Y, Silverstone T. Lithium and weight gain. Int Clin Psychopharmacol. 1990;3:217-225.
4. Baptista T, Teneud L, Contreras Q, et al. Lithium and body weight gain. Pharmacopsychiatry. 1995;2:35-44.
5. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf. 1996;5:329-342.
6. Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry. 1999;60(suppl 21):16-19.
7. Rockwell WJ, Ellinwood EH Jr, Trader DW. Psychotropic drugs promoting weight gain: health risks and treatment implications. South Med J. 1983;11:1407-1412.
8. Emslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry. 2000;3:179-184.
9. De Leon OA. Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder. Harv Rev Psychiatry. 2001;5:209-222.
10. Fatemi SH, Rapport DJ, Calabrese JR, Thuras P. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry. 1997;12:522-527.
11. Erfurth A, Kammerer C, Grunze H, Normann C, Walden J. An open label study of gabapentin in the treatment of acute mania. J Psychiatr Res. 1998;5:261-264.
12. McElroy SL, Soutullo CA, Keck PE Jr, Kmetz GF. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann Clin Psychiatry. 1997;2:99-103.
13. Maryanoff BE, Nortey SO, Gardocki JF, Shank RP, Dodgson SP. Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds. J Med Chem. 1987;5:880-887.
14. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia. 1994;2:450-460.
15. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997;3:167-179.
16. Marcotte D. Use of topiramate, a new antiepileptic, as a mood stabilizer. J Affect Disord. 1998;2-3:245-251.
17. Calabrese JR, Keck PE Jr, McElroy SL, Shelton MD. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol. 2001;3:340-342.
18. Chengappa KN, Rathore D, Levine J, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord. 1999;1:42-53.
19. Kusumakar V, Yatham L, Kutcher C, O'Donovan C. Preliminary, open-label study of topiramate in rapid cycling bipolar women [abstract]. Eur Neuropsychopharmacol. 1999;9(suppl 5):S357.
20. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry. 2000;12:1025-1033.
21. Schneiderman JH. Topiramate: pharmacokinetics and pharmacodynamics. Can J Neurol Sci. 1998;3:3-5.
22. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(suppl 1):S3-S9.
23. Chengappa KN, Levine J, Rathore D, Parepally H, Atzert R. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry. 2001;16:186-190.
24. Norton J, Potter D, Edwards K. Sustained weight loss associated with topiramate [abstract]. Epilepsia. 1997;38(suppl 3):60.
25. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37(suppl 2):S18-S22.
26. Rosenfeld WE, Schaefer PA, Pace K. Weight loss patterns with topiramate therapy [abstract]. Epilepsia. 1997;38(suppl 3):58
27. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
28. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;9:1417-1420.